<DOC>
	<DOCNO>NCT02388009</DOCNO>
	<brief_summary>This phase I , single-blind , randomize , placebo-controlled , single-center study healthy subject use staggered approach dose . 30 subject randomize receive 10 μg Flexyn2a candidate vaccine without adjuvant placebo .</brief_summary>
	<brief_title>Safety Tolerability Bioconjugate Vaccine Against Shigella Flexneri 2a</brief_title>
	<detailed_description>A total 30 subject randomly assign one 3 different arm order evaluate safety , tolerability immunogenicity candidate vaccine , formulate without adjuvant , outcome compare placebo control group . For active treatment group , 12 subject inject twice 10 μg Flexyn2a candidate vaccine 4 week apart . A control group 6 subject inject follow schedule placebo solution .</detailed_description>
	<mesh_term>Dysentery , Bacillary</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Healthy male female volunteer , age 18 50 year ( inclusive ) time enrollment . 2 . Signed informed consent form . 3 . Completion review comprehension test ( achieve &gt; 70 % accuracy ) 4 . Available required followup period schedule clinic visit . 5 . Women : negative pregnancy test understanding ( informed consent process ) become pregnant breastfeed study within twelve ( 12 ) week last vaccine dose . 1 . Health condition , opinion investigator , may interfere optimal participation study place volunteer increase risk adverse Events ( AEs ) . Study clinician , consultation PI , use clinical judgment case bycase basis ass safety risk criterion . The PI consult Research Monitor appropriate . 2 . Clinically significant abnormality physical examination . 3 . Clinically significant abnormality basic laboratory screening . 4 . Presence significant unexplained laboratory abnormality , opinion PI , may potentially confound analysis study result 5 . Regular use constipation , antacid antidiarrheal medication treatment . 6 . Abnormal stool pattern ( few 3 stool per week 3 per day ) loose/liquid stool occasionally . 7 . Use immunosuppressive drug corticosteroid chemotherapeutics may influence antibody development . 8 . Women currently nurse . 9 . Participation research involve another investigational product ( defined receipt investigational product exposure invasive investigational device ) within 30 day plan date first vaccination anytime throughout duration study . 10 . Positive blood test HBsAg , hepatitis C Virus ( HCV ) , HIV1 . 11 . Positive blood test HLAB27 . 12 . Immunosuppressive illness immunoglobulin deficiency ( serum immunoglobulin A level &lt; 7 mg/dL limit detection assay ) . 13 . Family history congenital hereditary immunodeficiency . 14 . Treatment immunoglobulins blood product within 3 month first candidate vaccine injection . 15 . History microbiologically confirm Shigella infection . 16 . Personal family history inflammatory arthritis . 17 . Personal family history irritable bowel syndrome . 18 . Received previous experimental Shigella vaccine live Shigella challenge . 19 . Have diarrhea travel outside United States live 2 month past 3 year country potentially high Shigella infection rate , include Africa , South America , Central America , Asia ( except Japan ) . 20 . Occupation involve handle Shigella bacteria currently , past 3 year . 21 . History allergy vaccine . 22 . History allergy aluminum hydroxide . 23 . Serum immunoglobulin G endpoint titer ≥ 2500 Shigella Lipopolysaccharide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>bioconjugate vaccine</keyword>
	<keyword>safety</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>shigellosis</keyword>
</DOC>